{"id":51254,"date":"2025-06-07T13:00:48","date_gmt":"2025-06-07T13:00:48","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=51254"},"modified":"2025-06-18T19:55:33","modified_gmt":"2025-06-18T19:55:33","slug":"similar-weight-increases-with-dolutegravir-and-bictegravir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/51254","title":{"rendered":"Risk of metabolic syndrome when starting ART with bictegravir vs dolutegravir"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>This randomised, open-label study reported the incidence of developing metabolic syndrome by 48 weeks in 278 people starting their first ART with second-generation INSTIs.<\/strong><\/p>\n<p>The incidence of metabolic syndrom was 6 (3.9%) vs 10 (6.3%) in participants starting with BIC\/TAF\/FTC vs DTG\/ABC\/3TC arms, respectively, with no significant difference between groups. In the BIC\/TAF\/FTC group, 24 participants (9%) experienced a weight gain of \u226510% vs 16 participants (6%) in the BIC\/TAF\/FTC vs DTG\/ABC\/3TC arms, respectively, (p = 0.72).<\/p>\n<p>Risk factors for metabolic syndrome were age \u226540 years, baseline BMI \u226525 kg\/m<sup>2<\/sup>, and baseline visceral fat \u22655 cm prior to ART initiation.<\/p>\n<p>Reference<\/p>\n<p>Mata Mar\u00edn JA et al. Incidence of metabolic syndrome in people with HIV without experience to antiretroviral therapy who start dolutegravir based-regimen compared with bictegravir based-regimen after 48 weeks (MICTLAN trial). AIDS ():10.1097\/QAD.0000000000004259. (5 June 2025).<br \/>\n<a href=\"https:\/\/journals.lww.com\/aidsonline\/abstract\/9900\/incidence_of_metabolic_syndrome_in_people_with_hiv.726.aspx\">https:\/\/journals.lww.com\/aidsonline\/abstract\/9900\/incidence_of_metabolic_syndrome_in_people_with_hiv.726.aspx<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base This randomised, open-label study reported the incidence of developing metabolic syndrome by 48 weeks in 278 people starting their first ART with second-generation INSTIs. The incidence of metabolic syndrom was 6 (3.9%) vs 10 (6.3%) in &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[343,8,27],"tags":[],"class_list":["post-51254","post","type-post","status-publish","format-standard","hentry","category-journal-scan","category-side-effects","category-weight-diabetes-metabolic-complications"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/51254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=51254"}],"version-history":[{"count":13,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/51254\/revisions"}],"predecessor-version":[{"id":51322,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/51254\/revisions\/51322"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=51254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=51254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=51254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}